Neurologic Disorders Therapeutics Market Size to Grow by USD 33.46 billion, Approval Of Novel Drugs to Boost Market Growth

NEW YORK, Grows. 2, 2022 /PRNewswire/ — The “Neurologic Disorders Therapeutics Market by Application (CNS and PNS) and Geography (North America, Europe, Asiaand Rest of World (ROW)) – Forecast and Analysis 2022-2026″ report has been added to Technavio’s offerings. The potential growth difference for the neurologic disorders therapeutics market size between 2021 and 2026 is USD 33.46 bn. To get the CAGR and the YOY growth rate, Request a Sample Report.

Technavio has announced its latest market research report titled Neurologic Disorders Therapeutics Market by Application and Geography – Forecast and Analysis 2022-2026

Key Market Dynamics:

  • Market Driver: The approval of novel drugs is driving the growth of the market. Several drugs have been approved for the treatment of neurological indications such as schizophrenia, bipolar disorder, depression, ADHD, and OCD. For instance, in April 2021, the US FDA approved Qelbree of Supernus Pharmaceuticals for treating ADHD in children aged between 6 and 17 years. Moreover, several other drugs for the treatment of indications such as ADHD, schizophrenia, and bipolar disorder have received marketing approval from the US FDA and the EMA. The rising number of drug approvals is expected to address the unmet need, which will contribute to the growth of the global neurological disorders therapeutics market during the forecast period.

  • Market Challenge: The advent of neurostimulation devices is challenging the growth of the market. Non-invasive neuromodulation devices are expected to gain importance in the coming years. For instance, NeuroPace Inc. has developed the RNS System, which has been approved by the US FDA as an adjunctive treatment for adults with medically refractory partial seizures. Therefore, ongoing research activities and the recent approval of neuromodulation devices, along with their use for the treatment of various neurological disorders, will challenge the growth of the global neurological disorders therapeutics market during the forecast period.

Be up-to-date with the latest drivers, trends, and challenges in the market. View our Sample Report

Market Segmentation

North America will be the leading region with 37% of the market’s growth during the forecast period. The US and Canada are the key countries for the neurological disorders therapeutics market in North America. The growth of the market in the region will be driven by factors such as the strong dominance of generics. Moreover, market growth in this region will be faster than the growth of the market in other regions.

The CNS application segment will contribute the highest market share growth during the forecast period. Central nervous system (CNS) disorders affect the nervous system and can be classified into functional disorders and degeneration disorders. Recent drug approvals are expected to significantly benefit this segment, which will drive the neurological disorders therapeutics market growth during the forecast period.

Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a Sample Report

Some Companies Mentioned

  • AbbVie Inc.

  • Acadia Pharmaceuticals Inc.

  • Acorda Therapeutics Inc.

  • Bayer AG

  • Biogen Inc.

  • Eisai Co. Ltd.

  • F. Hoffmann La Roche Ltd.

  • GlaxoSmithKline Plc

  • H Lundbeck AS

  • Johnson and Johnson

  • Merck KGaA

  • Mylan NV

  • Novartis AG

  • Otsuka Holdings Co. Ltd.

  • Pfizer Inc.

  • Sanofi

  • Takeda Pharmaceutical Co. Ltd.

  • Teva Pharmaceutical Industries Ltd.

  • UCB SA


Want your report customized? Speak to an analyst and personalize your report according to your needs.

Related Reports

Neurodegenerative Diseases Therapeutics Market by Indication and Geography – Forecast and Analysis 2022-2026: The neurodegenerative diseases therapeutics market size is predicted to surge by USD 19.74 billion from 2021 to 2026.

Neuromuscular Disease Therapeutics Market by Type and Geography – Forecast and Analysis 2021-2025: The neuromuscular disease therapeutics market share is expected to increase by USD 4.46 billion from 2020 to 2025.

Neurologic Disorders Therapeutics Market Scope

Report Coverage


Page number


Base year


Forecast period


Growth momentum & CAGR

Accelerate at a CAGR of 5.44%

Market growth 2022-2026

USD 33.46 billion

Market structure


YoY growth (%)


Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 37%

Key consumer countries

US, Canada, UK, China, and India

Competitive landscape

Leading companies, competitive strategies, consumer engagement scope

Companies profiled

AbbVie Inc., Acadia Pharmaceuticals Inc., Acorda Therapeutics Inc., Bayer AG, Biogen Inc., Eisai Co. Ltd., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, H Lundbeck AS, Johnson and Johnson, Merck KGaA, Mylan NV, Novartis AG, Otsuka Holdings Co. Ltd., Pfizer Inc., Sanofi, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., UCB SA, and USWM LLC

Market Dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and future consumer dynamics, and market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get customized segments.

Browse Health Care Market Research Reports

Key Topics Covered:

1 Executive Summary

2 Market Landscape

3 Market Sizing

4 Five Forces Analysis

5 Market Segmentation by Application

6 Customer Landscape

7 Geographic Landscape

8 Drivers, Challenges, and Trends

9 Vendor Landscape

10 Vendor Analysis

11 Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]

Technavio (PRNewsfoto/Technavio)

Technavio (PRNewsfoto/Technavio)



View original content to download multimedia: -drugs-to-boost-market-growth—technavio-301597582.html

SOURCE Technavio

Leave a Comment